SUPRANE Drug Patent Profile

✉ Email this page to a colleague

When do Suprane patents expire, and when can generic versions of Suprane launch?

Suprane is a drug marketed by Baxter Hlthcare and is included in one NDA.

The generic ingredient in SUPRANE is desflurane. There are three drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the desflurane profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Suprane

A generic version of SUPRANE was approved as desflurane by SHANGHAI HENGRUI on February 26^th, 2018.

Sign Up

AI Research Assistant

Questions you can ask:

What is the 5 year forecast for SUPRANE?
What are the global sales for SUPRANE?
What is Average Wholesale Price for SUPRANE?

Summary for SUPRANE

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	3
Raw Ingredient (Bulk) Api Vendors:	55
Clinical Trials:	35
Patent Applications:	1,352
Formulation / Manufacturing:	see details
Drug Prices:	Drug price information for SUPRANE
What excipients (inactive ingredients) are in SUPRANE?	SUPRANE excipients list
DailyMed Link:	SUPRANE at DailyMed

Drug patent expirations by year for SUPRANE

Recent Clinical Trials for SUPRANE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
National Cancer Institute, Egypt	N/A
Sefako Makgatho Health Sciences University	N/A
GAMZE PİRİNÇ ŞAŞIOĞLU	N/A

See all SUPRANE clinical trials

Pharmacology for SUPRANE

Drug Class	General Anesthetic
Physiological Effect	General Anesthesia

Paragraph IV (Patent) Challenges for SUPRANE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
SUPRANE	Inhalation	desflurane	99.9%	020118	1	2008-09-11

US Patents and Regulatory Information for SUPRANE

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Baxter Hlthcare	SUPRANE	desflurane	LIQUID;INHALATION	020118-001	Sep 18, 1992	AN	RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for SUPRANE

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Baxter Hlthcare	SUPRANE	desflurane	LIQUID;INHALATION	020118-001	Sep 18, 1992	⤷ Sign Up	⤷ Sign Up
Baxter Hlthcare	SUPRANE	desflurane	LIQUID;INHALATION	020118-001	Sep 18, 1992	⤷ Sign Up	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

International Patents for SUPRANE

See the table below for patents covering SUPRANE around the world.

Subscribe to access the full database, or Sign Up
Country	Patent Number	Title	Estimated Expiration
Canada	2100658		⤷ Sign Up
Finland	933326		⤷ Sign Up
South Korea	100198205		⤷ Sign Up
European Patent Office	0568564	RECIPIENT POUR AGENT ANESTHESIQUE LIQUIDE (A CONTAINER FOR LIQUID ANAESTHETIC AGENT)	⤷ Sign Up
Japan	H0376286		⤷ Sign Up
Japan	H06504463		⤷ Sign Up
>Country	>Patent Number	>Title	>Estimated Expiration

Supplementary Protection Certificates for SUPRANE

Subscribe to access the full database, or Sign Up
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0285237	95C0008	Belgium	⤷ Sign Up	PRODUCT NAME: ESTRADIOL, HEMIHYDRATE; NAT. REGISTRATION NO/DATE: NL 19489 19941107; FIRST REGISTRATION: FR - NL 19489 19941107
0285237	94C0006	France	⤷ Sign Up	PRODUCT NAME: DIDANOSINE; NAT. REG.: 203 IS 225 F 3 19930331; FIRST REG.: FR 557 386-4 19920505
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description